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http://dx.doi.org/10.1016/j.kjms.201Abstract Acromegaly is always complicated with comorbidities and increased mortality. The
disease activity and mortality outcomes are highly correlated to the level of growth hormone
and insulin-like growth factor 1. A variety of clinical manifestations of acromegaly have been
reported. We present a unique case where a 49-year-old male was diagnosed with acromegaly
with a first manifestation as an episode of diabetic ketoacidosis. Because he refused any sug-
gestion of treatment, a recurrent episode of diabetic ketoacidosis with pituitary apoplexy
occurred. A huge B-cell lymphoma displaying as a huge facial mass followed within 1 year of
the diagnosis of acromegaly. Death from advanced cancer ensued 3 years later. This clinical
experience strongly reinforces the urgency of controlling growth hormone and insulin-like
growth factor 1 as soon as possible once acromegaly is diagnosed.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The clinical characteristics of acromegaly are mainly
attributed to a sustained hypersecretion of growth hor-
mone (GH) by pituitary adenoma. The population incidencef Endocrinology and Meta-
ine, Kaohsiung Medical Uni-
iversity, 100 Tzyou 1st Road,
du.tw (P.-J. Hsiao).
hsiung Medical University. Publish
3.08.002of acromegaly is 3e4 cases per million, and its prevalence is
about 60 cases per million [1,2]. Complications of acro-
megaly broadly involve rheumatologic arthropathies, neu-
ropathies, cardiomyopathy, metabolic abnormalities,
respiratory compromise, and neoplasia. The prognosis and
outcome of acromegaly depends on whether or not it is
treated [1,3].
Pituitary apoplexy is defined as pituitary hemorrhage
occurring spontaneously in a preexisting nonfunctional or
functional pituitary macroadenoma. Its reported incidence
is very low (0.6e10.5%) [4,5]. This life-threatening conse-
quence is a clinical challenge owing to complicationsed by Elsevier Taiwan LLC. All rights reserved.
688 H.-J. Jiang et al.including severe headache, risk of vision loss, cardiovas-
cular collapse, and endocrine crisis [6].
Overall, mortality from acromegaly has been estimated
to increase 2e3-fold, and death is likely to occur 10 years
earlier than in comparably healthy individuals [7]. As re-
ported in series studies, 60% of patients died of cardiovas-
cular diseases, 25% of respiratory diseases, and 15%
succumbed to cancer [2]. The comorbidity and mortality of
acromegaly are correlated to the levels of GH prior to and
after treatment, the insulin-like growth factor I (IGF-1)
level, and the patient’s age, tumor size, degree of tumor
invasion, and duration prior to diagnosis [1].
Here, we describe a patient with acromegaly first pre-
senting with an episode of diabetic ketoacidosis (DKA).
Recurrent DKA ensued concurrently with pituitary
apoplexy. A malignant lymphoma grew rapidly within
1 year.
Case report
In August 2008, a 49-year-old male was sent to the emergency
unit because of polyuria, polydipsia, and shortness of breath
for 2weeks.He also had a rapid bodyweight loss of 17 kgwithin
1 year. He denied any previous illness or contributory family
history. DKA was diagnosed according to blood glucose of
592mg/dL, blood ketone 4.3mmol/L, andmetabolic acidemia
(pH 7.30, pCO2 28.5 mmHg, bicarbonate14.7 mmol/L). Newly
diagnosed diabetes mellitus was established by hemoglobin
A1c (HbA1c) 17.8%, and screening for negative glutamic acid
decarboxylase autoantibody.
Acromegaly was suspected because typical characteris-
tics were noted including body height of 185 cm, body
weight of 87 kg, coarse facial features, large fleshy nose,
frontal bossing, jaw prognathism, acral overgrowth, and
thickening skin. Acromegaly was confirmed by elevated GH
180.1 mIU/mL (normal <15 mIU/mL, equal to 5 mg/L), IGF-1
839.5 ng/mL (normal 41e272 ng/mL for males 40e50 years
of age), and prolactin 293.4 ng/mL (normal 1e18 ng/mL).
Imaging studies revealed sellar enlargement with a double
floor contour of the sella turcica by skull X-ray and pituitary
macroadenoma (1.88 cm  1.80 cm  2.11 cm) by magnetic
resonance imaging (MRI; Fig. 1). Diabetes secondary to
acromegaly was diagnosed and insulin therapy was used toFigure 1. Pituitary macroadenoma (1.88 cm  1.80 cm  2.11 cm
magnetic resonance imaging.control blood glucose. Transphenoidal surgical intervention
was highly recommended by an experienced neurosurgeon.
However, this patient refused treatment and was lost to
follow-up after discharge.
Unfortunately, the patient returned to our hospital due
to a sudden onset of severe headache and a recurrent DKA
episode 2 months later. Pituitary apoplexy was documented
by sella MRI (Fig. 2) showing a marked hemorrhage density
over the pituitary macroadenoma with interval enlarge-
ment (2.20 cm  1.96 cm  2.00 cm). Because there was no
evidence of ophthalmoplegia or pituitary failure (cortisol
9.2 mg/dL, TSH 0.76 mU/mL, Free T4 0.7 ng/dL), his con-
dition was improved by supportive care. Surgical interven-
tion, radiotherapy, and intensive insulin therapy were well
indicated and advised during a team conference by several
experts, but the patient denied further treatment again
without visiting our outpatient clinic.
In June 2009, the patient visited our endocrine clinic due
to a progressive bulging mass over the right face within
2 weeks. He presented with complications from hypergly-
cemia once again (blood glucose 764 mg/dL, blood ketone
3.4 mmol/L, and HbA1c 17.5%) owing to interruption of the
insulin injection. He also declared that he had sought
alternative traditional herb medicine within this period. A
computed tomography scan displayed a soft tissue mass
6.4 cm  4.9 cm  4.4 cm in size over the right maxillary
sinus with extensive invasion of the sinus wall, orbital floor,
nasal cavity, and cheek (Fig. 3). B-cell lymphoma was
diagnosed by biopsy. His endocrine function was assessed as
serum GH > 175 mIU/mL, IGF-1 823.10 ng/mL, and prolactin
196.4 ng/mL. Staging and further chemotherapy were sug-
gested by an oncologist, but this patient still insisted on
continuing his herbal medicine regimen.
In August 2012, he visited a urologist due to an
enlargement of the left scrotum, intolerable dyspnea, and
general weakness. Lymphoma with advanced peritoneal
and pleural carcinomatosis was identified by a serial ex-
amination. The sella MRI showed interval shrinkage of the
adenoma (1.46 cm  1.80 cm  1.80 cm). In the meantime,
his GH (78.44 mIU/mL) and IGF-1 (449.18 ng/mL) declined
and hypoglycemia became frequent. As a result of his
intractable clinical respiratory failure, he died in
September 2012.) shown in T1 phase with contrast (coronal and sagittal view) by
Figure 2. Pituitary apoplexy (hemorrhage marked by arrowhead) in a macroadenoma with interval enlargement
(2.20 cm  1.96 cm  2.00 cm) shown in T1 phase with contrast (coronal and sagittal view) by magnetic resonance imaging.
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This rare case of catastrophic acromegaly proceeding
rapidly to mortality provides many informative features for
the clinician.
Abnormalities of glucose metabolism are common in
acromegaly. Overt diabetes develops in 10e15% of patients
[8]. There are many case reports of acromegaly presenting
with DKA, which is attributable to insulin resistance [9].
Insulin resistance results in reduced lipoprotein lipase ac-
tivity, reduced catabolism of very-low-density lipoproteins,
increasing lipolysis of adipose, and increasing fatty acid
influx to the liver. GH physiologically counteracts the in-
sulin to stimulate lipolysis and promote triglyceride hy-
drolysis into free fatty acids [10]. Interaction between the
insulin resistance and elevated GH help explain the DKA in
acromegaly.
Pituitary apoplexy is a life-threatening emergency pre-
senting as an acute episode of severe headache, visual loss,
and hypopituitarism. It usually occurs spontaneously but
can be predisposed by pregnancy, head injury, uncontrolled
hypertension or diabetes, anticoagulant therapy, or pitui-
tary stimulation testing [5,6]. Three mechanisms have beenFigure 3. Computed tomography (transverse and coronal view)
tumor over the right maxillary sinus with invasion and destruction
cheek.stated for pituitary apoplexy. First, the tumor expansion
outgrows its blood supply. Second, tumor compression re-
sults in circulation extravasation beyond the dura. Third, an
intrinsic aneurysm over the tumor tends to bleed [4,5].
Surgical decompression is suggested to rescue visual acuity.
Hypopituitarism is supported by fluid resuscitation and
hormone replacement [5]. Some cases have experienced
spontaneous remission of acromegaly after pituitary
apoplexy [11]. Our patient had no visual defect and hypo-
pituitarism because of the limited hemorrhage in the ade-
noma, so elevated GH persisted.
Retrospective studies have reported a cancer-related
mortality of 9e50% in acromegaly. Most studies have
demonstrated a moderate (1.5-fold to 4-fold) increase in
cancer risk in patients with acromegaly, especially neo-
plasms of the colon, breast, thyroid, and hematological
system [7,12]. However, some investigations have not
found an increased incidence of cancer mortality in acro-
megaly [13,14]. The inconclusive epidemiologic analyses of
cancer incidence, prevalence, and mortality of acromegaly
have been explained by limited case numbers and/or
reporting biases. Substantial evidence has emerged to
support the role of GH/IGF-1 in tumor initiation andof the face revealed a 4.4 cm  4.9 cm  6.4 cm soft tissue
of the sinus wall, orbital floor, nasal cavity, ethmoid sinus, and
690 H.-J. Jiang et al.progression, which are synergistically mediated by the
mitogenic and antiapoptotic effects of GH and IGF-1 to
activate cell proliferation and transformation in many tis-
sues. Therefore, GH/IGF-1 represents a clinical parameter
to assess the disease activity of acromegaly [15]. Our pa-
tient developed a B-cell lymphoma within 1 year of his
diagnosis of acromegaly and died within 3 years. The un-
treated status of this patient’s persistent elevation of GH/
IGF-1 rationally may have contributed to lymphoma for-
mation and fatality.
Our patient presented with recurrent DKA, pituitary
apoplexy, and lymphoma within 1 year after diagnosis of
acromegaly. This unusual case experience of rapid pro-
gression strongly highlights the urgent necessity of con-
trolling GH/IGF-1 as soon as the diagnosis of acromegaly is
established.
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